$9.93 Million in Sales Expected for Affimed (NASDAQ:AFMD) This Quarter

Equities analysts expect Affimed (NASDAQ:AFMDGet Rating) to announce $9.93 million in sales for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Affimed’s earnings, with the highest sales estimate coming in at $13.82 million and the lowest estimate coming in at $4.42 million. Affimed posted sales of $14.05 million during the same quarter last year, which suggests a negative year over year growth rate of 29.3%. The business is expected to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Affimed will report full year sales of $39.19 million for the current financial year, with estimates ranging from $16.57 million to $68.51 million. For the next fiscal year, analysts expect that the business will post sales of $38.15 million, with estimates ranging from $2.21 million to $81.40 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Affimed.

Affimed (NASDAQ:AFMDGet Rating) last issued its quarterly earnings results on Thursday, March 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). The firm had revenue of $11.82 million for the quarter, compared to analysts’ expectations of $10.30 million. Affimed had a negative net margin of 149.76% and a negative return on equity of 40.66%. During the same period in the prior year, the company earned ($0.20) EPS.

A number of research firms have recently weighed in on AFMD. Zacks Investment Research raised shares of Affimed from a “sell” rating to a “hold” rating in a research report on Tuesday, April 5th. Cantor Fitzgerald assumed coverage on shares of Affimed in a report on Wednesday, February 23rd. They issued an “overweight” rating and a $12.00 target price for the company. StockNews.com downgraded shares of Affimed from a “hold” rating to a “sell” rating in a report on Monday, March 28th. Finally, Piper Sandler assumed coverage on shares of Affimed in a research report on Wednesday, March 30th. They issued an “overweight” rating and a $7.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Affimed currently has a consensus rating of “Buy” and an average target price of $10.17.

Shares of AFMD opened at $3.12 on Wednesday. The firm has a 50 day moving average price of $3.97 and a 200-day moving average price of $4.73. Affimed has a fifty-two week low of $2.88 and a fifty-two week high of $9.23. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.19 and a current ratio of 3.20. The firm has a market cap of $385.07 million, a price-to-earnings ratio of -5.47 and a beta of 2.49.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Asset Management L.P. raised its holdings in Affimed by 93.6% during the fourth quarter. Point72 Asset Management L.P. now owns 11,855,151 shares of the biopharmaceutical company’s stock worth $65,440,000 after purchasing an additional 5,732,500 shares in the last quarter. BlackRock Inc. grew its position in shares of Affimed by 1.0% in the fourth quarter. BlackRock Inc. now owns 6,848,983 shares of the biopharmaceutical company’s stock valued at $37,805,000 after purchasing an additional 70,893 shares during the last quarter. 683 Capital Management LLC grew its position in shares of Affimed by 5.3% in the fourth quarter. 683 Capital Management LLC now owns 5,900,559 shares of the biopharmaceutical company’s stock valued at $32,571,000 after purchasing an additional 298,246 shares during the last quarter. Pictet Asset Management SA boosted its position in Affimed by 15.9% during the fourth quarter. Pictet Asset Management SA now owns 4,627,458 shares of the biopharmaceutical company’s stock worth $25,544,000 after acquiring an additional 636,342 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in Affimed by 47.5% during the third quarter. Goldman Sachs Group Inc. now owns 2,846,200 shares of the biopharmaceutical company’s stock worth $17,590,000 after acquiring an additional 916,189 shares during the last quarter. 63.47% of the stock is owned by institutional investors and hedge funds.

Affimed Company Profile (Get Rating)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma.

Further Reading

Get a free copy of the Zacks research report on Affimed (AFMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.